for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AmerisourceBergen Corp.

ABC.N

Latest Trade

97.80USD

Change

-1.72(-1.73%)

Volume

192,273

Today's Range

97.22

 - 

100.67

52 Week Range

72.20

 - 

106.33

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
99.52
Open
99.56
Volume
192,273
3M AVG Volume
18.26
Today's High
100.67
Today's Low
97.22
52 Week High
106.33
52 Week Low
72.20
Shares Out (MIL)
204.14
Market Cap (MIL)
20,316.19
Forward P/E
12.65
Dividend (Yield %)
1.69

Next Event

Q4 2020 Amerisourcebergen Corp Earnings Call

Latest Developments

More

Amerisourcebergen Units Entered Amended & Restated Receivables Sale Agreement

HHS Says Gilead Anticipates Producing Sufficient Quantities Of Veklury To Meet Current Needs

U.S. States Seek $26.4 Bln From Drug Companies In Opioid Litigation - WSJ

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AmerisourceBergen Corp.

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company's segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.

Industry

Biotechnology & Drugs

Contact Info

1300 Morris Dr

CHESTERBROOK, PA

19087-5594

United States

+1.610.7277000

Executive Leadership

Steven H. Collis

Chairman of the Board, President, Chief Executive Officer

James F. Cleary

Chief Financial Officer, Executive Vice President

Silvana Battaglia

Chief Human Resource Officer, Executive Vice President

Gina K. Clark

Executive Vice President, Chief Communications & Administration Officer

John G. Chou

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.37 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

153.1K

2018

167.9K

2019

179.6K

2020(E)

188.7K
EPS (USD)

2017

5.880

2018

6.490

2019

7.090

2020(E)

7.869
Price To Earnings (TTM)
13.15
Price To Sales (TTM)
0.11
Price To Book (MRQ)
5.26
Price To Cash Flow (TTM)
10.17
Total Debt To Equity (MRQ)
107.34
LT Debt To Equity (MRQ)
93.87
Return on Investment (TTM)
16.08
Return on Equity (TTM)
3.98

Latest News

Latest News

BRIEF-U.S. States Seek $26.4 Bln From Drug Companies In Opioid Litigation - WSJ

* U.S. STATES SEEK $26.4 BILLION FROM DRUG COMPANIES IN OPIOID LITIGATION- WSJ

BRIEF-Amerisourcebergen Selected By Deciphera Pharmaceuticals To Support Qinlock

* AMERISOURCEBERGEN SELECTED BY DECIPHERA PHARMACEUTICALS TO SUPPORT QINLOCK™ Source text for Eikon: Further company coverage:

BRIEF-AmerisourceBergen Corp Prices $500 Mln 2.800% Senior Notes Due 2030

* AMERISOURCEBERGEN PRICES $500 MILLION 2.800% SENIOR NOTES DUE 2030 Source text for Eikon: Further company coverage:

BRIEF-Amerisourcebergen Sees 2020 Rev Growth In Low- To Mid-Single Digit Percent Range

* AMERISOURCEBERGEN REPORTS FISCAL 2020 SECOND QUARTER RESULTS

Exclusive: AmerisourceBergen eyes Walgreens' drug distribution business

AmerisourceBergen Corp <ABC.N>, one of the largest U.S. drug distributors, has approached Walgreens Boots Alliance Inc <WBA.O> to explore a deal for its pharmaceutical wholesaling division, people familiar with the matter said on Monday.

BRIEF-PIRC Recommends Amerisourcebergen Shareholders To Vote Against Election Of Steven H Collis As Director

* PROXY ADVISORY FIRM PIRC RECOMMENDS AMERISOURCEBERGEN CORP SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO ELECT CEO STEVEN H COLLIS AS DIRECTOR

Dela. judge okays Supreme Court review of controversial books-and-records decision

Vice-Chancellor Travis Laster of Delaware Chancery Court signaled Wednesday that he really did intend to reset the course of books-and-records litigation when he ruled last month that the wholesale pharmaceutical distributor AmerisourceBergen give shareholders formal board...

Delaware Chancery judge pushes back against limits on books-and-records demands

There is a reasonable possibility, according to Vice-Chancellor Travis Laster, that shareholders of the wholesale pharmaceutical distributor AmerisourceBergen Corporation will turn out to have an actionable claim that the company’s directors breached their fiduciary duties...

AmerisourceBergen to pay $625 million in U.S. civil fraud settlement

AmerisourceBergen Corp, one of the largest U.S. drug wholesalers, will pay $625 million to resolve civil fraud charges over the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors.

AmerisourceBergen in $625 mln drug distribution settlement, New York says

AmerisourceBergen Corp will pay the U.S. government and various states $625 million to resolve claims over the illegal distribution of adulterated and misbranded drugs, New York Attorney General Barbara Underwood said on Monday.

UPDATE 1-U.S. subpoenas AmerisourceBergen over opioid products

Drug wholesale distributor AmerisourceBergen Corp said on Thursday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to opioid products and its communications with a drugmaker.

U.S. subpoenas AmerisourceBergen over opioid products

Drug wholesale distributor AmerisourceBergen Corp said on Thursday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to opioid products and its communications with a drugmaker.

AmerisourceBergen sees Memphis plant back on track by 2019; shares rise

Drug distributor AmerisourceBergen Corp <ABC.N> posted a better-than-expected quarterly profit on Wednesday and said it expects its Memphis facility to be fully operational by fiscal 2019, sending its shares up 5 percent.

BRIEF-AmerisourceBergen Reports Q2 Earnings Per Share $1.29

* AMERISOURCEBERGEN REPORTS FISCAL 2018 SECOND QUARTER RESULTS

AmerisourceBergen quarterly profit falls 30 percent

Drug distributor AmerisourceBergen Corp on Wednesday posted a 30 percent fall in second-quarter profit hurt by high operating expenses.

BRIEF-Amerisourcebergen Production At Pharmedium's Memphis Outsourcing Facility Remains Voluntarily Suspended

* PRODUCTION AT PHARMEDIUM'S MEMPHIS OUTSOURCING FACILITY REMAINS VOLUNTARILY SUSPENDED

Kentucky sues drug distributor AmerisourceBergen over opioid epidemic

Kentucky's attorney general on Thursday sued AmerisourceBergen Corp, accusing the drug distributor of contributing to opioid abuse in the state by filling suspiciously large or frequent pharmacy orders of prescription painkillers.

BRIEF-AmerisourceBergen Says Stockholders Rejected Proposal To Urge Board To Report On Governance Measures Implemented Related To Opioids

* AMERISOURCEBERGEN SAYS STOCKHOLDERS REJECTED PROPOSAL TO URGE BOARD TO REPORT ON GOVERNANCE MEASURES IMPLEMENTED RELATED TO OPIOIDS - SEC FILING Source text: (http://bit.ly/2HZhCXW) Further company coverage:

BRIEF-Deal talks between Walgreens and AmerisourceBergen have ended without an agreement- CNBC

* TALKS BETWEEN WALGREENS AND AMERISOURCEBERGEN ABOUT AN ACQUISITION OF THE WHOLESALE DRUG DISTRIBUTOR HAVE ENDED WITHOUT AN AGREEMENT - CNBC, CITING SOURCES Source text: http://cnb.cx/2HP99qj Further company coverage:

Amerisource deal may not keep Walgreens competitive: analysts

Walgreens' potential deal for drug distributor AmerisourceBergen will boost its cash flow and push it deeper into a lucrative specialty pharmacy market, but may fail to keep it competitive in an evolving U.S. healthcare sector, analysts said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up